In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.02.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Matilde Bocci und 8 weiteren Autor:innen. Beteiligte Einrichtung: Philochem AG, R&D Department, CH-8112 Otelfingen, Switzerland. Electronic address: matilde.bocci@philochem.ch. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunoconjugates. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 74 Literaturangaben.
Abstract (Originalsprache)
Small molecule-drug conjugates (SMDCs) are increasingly considered as a therapeutic alternative to antibody-drug conjugates (ADCs) for cancer therapy. OncoFAP is an ultra-high affinity ligand of Fibroblast Activation Protein (FAP), a stromal tumor-associated antigen overexpressed in a wide variety of solid human malignancies. We have recently reported the development of non-internalizing OncoFAP-based SMDCs, which are activated by FAP thanks to selective proteolytic cleavage of the -GlyPro- linker with consequent release of monomethyl auristatin E (MMAE) in the tumor microenvironment. In this article, we describe the generation and the in vivo characterization of FAP-cleavable OncoFAP-drug conjugates based on potent topoisomerase I inhibitors (DXd, SN-38, and exatecan) and an anti-tubulin payload (MMAE), which are already exploited in clinical-stage and approved ADCs. The Glycine-Proline FAP-cleavable technology was directly benchmarked against linkers found in Adcetris™, Enhertu™, and Trodelvy™ structures by means of in vivo therapeutic experiments in mice bearing tumors with cellular or stromal FAP expression. OncoFAP-GlyPro-Exatecan and OncoFAP-GlyPro-MMAE emerged as the most efficacious anti-cancer therapeutics against FAP-positive cellular models. OncoFAP-GlyPro-MMAE exhibited a potent antitumor activity also against stromal models, and was therefore selected for clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Philochem AG, R&D Department, CH-8112 Otelfingen, Switzerland. Electronic address: matilde.bocci@philochem.ch.
- Philochem AG, R&D Department, CH-8112 Otelfingen, Switzerland.
- Swiss Federal Institute of Technology, Department of Chemistry and Applied Biosciences, Zurich CH-8093, Switzerland; Philogen S.p.A., Siena 53100, Italy.
- Philochem AG, R&D Department, CH-8112 Otelfingen, Switzerland. Electronic address: samuele.cazzamalli@philochem.ch.
- Philochem AG, R&D Department, CH-8112 Otelfingen, Switzerland. Electronic address: andrea.galbiati@philochem.ch.
Zitieren
APA
Bocci, M., Zana, A., Principi, L., Lucaroni, L., Prati, L., Gilardoni, E., Neri, D., Cazzamalli, S., & Galbiati, A. (2024). In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.02.014
Vancouver
Bocci M, Zana A, Principi L, Lucaroni L, Prati L, Gilardoni E, et al. In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.02.014
BibTeX
@article{Bocci2024,
author = {Bocci, Matilde and Zana, Aureliano and Principi, Lucrezia and Lucaroni, Laura and Prati, Luca and Gilardoni, Ettore and Neri, Dario and Cazzamalli, Samuele and Galbiati, Andrea},
title = {In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.02.014}
}
EUVIMED